BioSpace News Archive

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia, being held February 19-22, 2023 in Banff, Alberta, Canada.

Valneva SE, a specialty vaccine company, announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553.

FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory, and metabolic disorders, announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse.

Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, announced that Encision has signed a Proof of Concept Services Agreement with Vicarious Surgical Inc.

Lemonex Inc., a biotechnology company pioneering messenger RNA and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February that an Investigational New Drug application has been submitted to the Ministry of Food and Drug Safety for mRNA vaccine LEM-mR203 with its nano-drug delivery platform, DegradaBALL® on 20th of January.

BioMed X announced the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target antigens of human T cell receptors.

Insulet Corporation announced that management will present at two upcoming investor conferences: The Raymond James & Associates 44th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 7, 2023 at 9:15 a.m.

TORONTO, Feb. 14, 2023 /PRNewswire/ - MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication of “Point-of-care fluorescence imaging reveals extent of bacterial load in diabetic foot ulcers"1 in International Wound Journal.